摘要
目的探讨双倍剂量氯吡格雷治疗冠状动脉介入(PCI)术后氯吡格雷抵抗患者的疗效及安全性。方法 152例PCI术后氯吡格雷抵抗的冠心病患者随机分为观察组(n=76)与对照组(n=76)。观察组术后给予双倍剂量氯吡格雷治疗,对照组给予常规剂量氯吡格雷,其余治疗均一致。比较2组患者的临床疗效及安全性。结果 PCI术后第14、30、180天时,观察组血小板聚集率(PAR)均显著低于对照组(P<0.05);2组患者术后1个月内心血管不良事件发生率、病死率及出血情况比较均无显著差异(P>0.05);术后6个月观察组心血管不良事件发生率、病死率均显著低于对照组(P<0.05),但2组出血情况比较仍无显著差异(P>0.05)。结论应用双倍剂量氯吡格雷治疗PCI术后氯吡格雷抵抗患者能有效地降低PAR,改善患者预后,且并未增加出血风险,值得临床推广。
Objective To explore the clinical efficacy and security of double dosage of clopidogrel in the treatment of patients with clopidogrel resistance after percutaneous coronary intervention（PCI）. Methods 152 patients with clopidogrel resistance after PCI were randomly divided into observation group（n= 76）and control group（n= 76）. The observation group was treated with double dosage of clopidogrel, while the control group was treated with conventional dosage of clopidogrel. Clinical efficacy and security were compared between the two groups. Results Platelet aggregation rates（PAR）in the observation group were significantly lower than those in the control group at the time pointsof the 14th,30th and 180th days after PCI（P 0.05）. There were no significant difference of incidence rate of adverse cardiovascular events, mortality rate and bleeding at the time of one month after PCI between the two groups（P 0.05）. Incidence rate of adverse cardiovascular events and mortality rate in the observation group were significantly lower than those in the control group at the time of 6 months after PCI（P 0.05）, but there was no significant difference of bleeding between the two groups（P 0.05）. Conclusion Application of double dosage of clopidogrel in the treatment of patients with clopidogrel resistance after PCI can effectively reduce
出处
《实用临床医药杂志》
CAS
2014年第1期30-32,52,共4页
Journal of Clinical Medicine in Practice
关键词
冠脉介入
氯吡格雷抵抗
双倍剂量
疗效
安全性
percutaneous coronary intervention
clopidogrel resistance
double dosage
efficacy
security
